These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27587071)

  • 1. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.
    Ward T; Gordon J; Jones B; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; McEwan P
    Clin Drug Investig; 2017 Jan; 37(1):61-70. PubMed ID: 27587071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.
    Smith-Palmer J; Cerri K; Valentine W
    BMC Infect Dis; 2015 Jan; 15():19. PubMed ID: 25596623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.
    Fransen van de Putte DE; Makris M; Fischer K; Yee TT; Kirk L; van Erpecum KJ; Patch D; Posthouwer D; Mauser-Bunschoten EP
    J Hepatol; 2014 Jan; 60(1):39-45. PubMed ID: 23978717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
    Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C.
    McEwan P; Ward T; Bennett H; Kalsekar A; Webster S; Brenner M; Yuan Y
    PLoS One; 2015; 10(1):e0117334. PubMed ID: 25635922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
    Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
    Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.
    Ward T; Gordon J; Bennett H; Webster S; Sugrue D; Jones B; Brenner M; McEwan P
    Public Health; 2016 Dec; 141():42-51. PubMed ID: 27932014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):77-87. PubMed ID: 24032626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates.
    Gadiparthi C; Cholankeril G; Perumpail BJ; Yoo ER; Satapathy SK; Nair S; Ahmed A
    World J Gastroenterol; 2018 Jan; 24(3):315-322. PubMed ID: 29391754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
    Gimeno-Ballester V; Mar J; San Miguel R
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):285-94. PubMed ID: 26327360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.